Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study to Evaluate the Safety, Tolerability, Pharmacodynamics (PD) and Pharmacokinetics (PK) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in Healthy Volunteers

Next Previous
X
Search
Trial Profile

Phase I Study to Evaluate the Safety, Tolerability, Pharmacodynamics (PD) and Pharmacokinetics (PK) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in Healthy Volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Niclosamide (Primary)
  • Indications COVID 2019 infections; Lung disorders
  • Focus Adverse reactions
  • Sponsors Daewoong Pharmaceutical; Mankind Pharma

    • Most Recent Events

    • 09 Sep 2020 According to a Daewoong Pharmaceutical media release, the company has started administrating drug since 3rd Sep 2020 in this study. Till date, safety data from this study has been confirmed in the first treatment group and the clinical trial is going well.
    • 09 Sep 2020 Status changed from not yet recruiting to recruiting, according to a Daewoong Pharmaceutical media release.
    • 26 Aug 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top